Lithium

USMLE Step 1 trap: Underestimates how close toxic levels are to therapeutic levels for lithium. Lithium has a narrow therapeutic index (0.6–1.2 mEq/L for maintenance); toxicity can occur at levels only slightly above therapeutic, and early signs include tremor, GI upset, and polyuria.

Lithium is a first-line mood stabilizer for bipolar I disorder and one of the highest-yield drugs in psychiatry on USMLE Step 1. The exam tests it from multiple angles: straightforward recall of indications and toxicity signs, application of pharmacokinetics to clinical scenarios (e.g., a patient on a thiazide who becomes confused), and passage-based questions where you have to recognize a chronic complication like nephrogenic DI or hypothyroidism in a patient who's been on lithium for years. It's also one of the few drugs where the exam specifically tests a survival benefit — lithium uniquely reduces suicide and all-cause mortality in bipolar disorder, which is a fact most students don't know cold.

What makes lithium genuinely tricky is its narrow therapeutic index. Students routinely underestimate how close toxic levels are to therapeutic ones. The maintenance range is 0.6–1.2 mEq/L — toxic symptoms can appear just slightly above that. Early toxicity looks like tremor, nausea, and polyuria, which are easy to dismiss or confuse with side effects. The bigger conceptual trap is the drug interaction profile: NSAIDs and thiazide diuretics both raise lithium levels through renal mechanisms, and the exam loves to bury this in a vignette where a patient gets prescribed ibuprofen for back pain and then develops confusion.

On USMLE Step 1, you also need to know lithium's chronic organ effects as a package: nephrogenic diabetes insipidus (polyuria/polydipsia from collecting duct ADH resistance), hypothyroidism, and hyperparathyroidism with chronic use. The teratogenic risk is specific — Ebstein's anomaly, a downward displacement of the tricuspid valve. These are the kinds of details that appear in second-order questions where you have to connect the drug to an organ system effect or a neonatal finding.

From real student decks

92%have cards covering this topic

76%have mature cards

Well-covered in most decks — the challenge is retention, not exposure.

Common misconceptions

Common mistake

Wrong: Lithium toxicity only occurs at levels well above the therapeutic range.

Right: Lithium has a narrow therapeutic index (0.6–1.2 mEq/L for maintenance); toxicity can occur at levels only slightly above therapeutic, and early signs include tremor, GI upset, and polyuria.

Lithium's therapeutic index is genuinely narrow — the maintenance range tops out around 1.2 mEq/L, and early toxic symptoms can appear at 1.5 mEq/L or even lower. Students who think toxicity only occurs at dramatically elevated levels will miss vignettes where a patient on therapeutic lithium develops tremor and polyuria after a minor insult like dehydration. The mental model to build: lithium is like digoxin — a small change in level produces a big clinical change, and early symptoms (tremor, GI upset, polyuria) are the warning signs you act on.

Common mistake

Wrong: NSAIDs and thiazide diuretics are safe to use with lithium.

Right: NSAIDs (reduce renal prostaglandins) and thiazide diuretics (cause compensatory proximal tubule sodium/lithium reabsorption) both significantly raise lithium levels and can precipitate toxicity.

Both NSAIDs and thiazides raise lithium levels through renal mechanisms, not pharmacodynamic interactions — this is why students miss them. NSAIDs reduce prostaglandin-mediated afferent arteriole dilation, dropping GFR and lithium clearance. Thiazides cause sodium wasting, which triggers compensatory proximal tubule reabsorption of both sodium and lithium together (because the kidney handles lithium like sodium). The clinical result is the same: lithium accumulates. Whenever you see lithium in a vignette, scan the medication list for NSAIDs, thiazides, or ACE inhibitors.

Common mistake

Gap: Missing knowledge of lithium's chronic renal, thyroid, and teratogenic effects

Chronic lithium use causes nephrogenic diabetes insipidus (polyuria/polydipsia), hypothyroidism, and hyperparathyroidism, and is teratogenic (Ebstein's anomaly of the tricuspid valve).

Chronic lithium use causes a predictable set of organ effects that the exam tests as a package. In the kidney, lithium blocks ADH receptors in collecting duct principal cells, causing nephrogenic DI — patients get polyuria and polydipsia despite normal ADH levels. In the thyroid, lithium inhibits thyroid hormone synthesis and release, causing hypothyroidism (monitor TSH). In the parathyroid, lithium shifts the calcium set point, causing hypercalcemia and hyperparathyroidism. And in pregnancy, first-trimester exposure causes Ebstein's anomaly — remember it as the 'tricuspid valve displaced downward into the right ventricle.'

Common mistake

Gap: Missing knowledge that lithium uniquely reduces suicide risk among mood stabilizers

Lithium is the only mood stabilizer with robust evidence for reducing suicide and all-cause mortality in bipolar disorder, independent of its mood-stabilizing effect.

This is a gap most students have because it feels like a detail, but Step 1 tests it because it's mechanistically distinct from mood stabilization. Lithium reduces impulsive aggression and suicidality through serotonergic and neuroprotective effects, independent of whether it controls mania or depression. No other mood stabilizer — not valproate, not lamotrigine, not atypical antipsychotics — has the same mortality benefit in the data. In a question asking which medication to choose for a bipolar patient with prior suicide attempts, lithium is the right answer for this reason.

Free Deck audit

See if your Anki deck covers this topic.

Upload your deck →

Guided session

Stuck on this? An AI tutor that probes your understanding.

Start a session →

What the exam tests

Know lithium's indications — it's used for acute mania, bipolar maintenance, and augmentation of antidepressants — and know that it is uniquely the only mood stabilizer with robust evidence for reducing suicide risk and all-cause mortality in bipolar disorder.
Know the therapeutic range (0.6–1.2 mEq/L for maintenance, up to 1.5 for acute mania), what early and late toxicity looks like (tremor → confusion → seizures → cardiac arrhythmias), and what monitoring is required (renal function, thyroid, levels, and calcium).
Know lithium's chronic organ-system effects: nephrogenic diabetes insipidus, hypothyroidism, hyperparathyroidism, and the teratogenic risk of Ebstein's anomaly (tricuspid valve downward displacement).
Know which drugs and physiologic states raise lithium levels — NSAIDs (reduce renal prostaglandins, decrease GFR), thiazide diuretics (cause compensatory proximal tubule sodium/lithium reabsorption), dehydration, and low-sodium states all precipitate toxicity.

Can you avoid these mistakes?

A 42-year-old man with bipolar I disorder on lithium 900 mg/day starts taking ibuprofen for knee pain. Two weeks later he presents with coarse tremor, nausea, and confusion. His lithium level is 1.8 mEq/L. What is the mechanism by which ibuprofen raised his lithium level?

A woman who took lithium during the first trimester delivers a baby with a heart murmur. Echocardiogram shows displacement of the tricuspid valve leaflets into the right ventricle. What is this anomaly called, and which drug class is responsible?

A patient on long-term lithium therapy complains of drinking 4–5 liters of water per day and urinating constantly. Urine osmolality is low despite high serum osmolality and normal ADH levels. What is the diagnosis and the mechanism?

You are choosing a mood stabilizer for a patient with bipolar I disorder who has a history of two serious suicide attempts. Which agent has the strongest evidence for reducing suicide risk independent of mood stabilization, and why is it preferred over valproate in this clinical context?

Lithium

Common misconceptions

What the exam tests

Can you avoid these mistakes?

Related topics